Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genomic Shift

This article was originally published in Start Up

Executive Summary

Model organisms don't capture the same sense of scientific challenge that sequencing the largely completed human genome did. A genomic shift has occurred. One benchmark for that change is the sudden shrinkage of several sequencing markets related to the human genome, including instrumentation, raw data, and personnel.

You may also be interested in...

Disco(very) Dancing to a Slower Beat?

SARS. Iraq. Recession. Terrorists. Risk aversion is in the air, and it hardly seems surprising that leading suppliers of discovery tools for studying gene expression are warning that their own businesses may suffer going forward. Roche and Merck say it's discovery-business-as-usual in Big Pharma, despite the fact that capital spending in the biotech sector has slowed. But some Wall Street analysts contend that customers are moving away from gene expression as a discovery vehicle. And such a point of view creates disturbing implications for the still unprofitable Affymetrix, which has yet to demonstrate that selling gene-based microarrays and related instrument systems is a model for a sustainable business.

CTG Pharma SRL

CTG Pharma SRL's founders believe that the unique properties of hydrogen sulfide (H2S) hold the key to exciting new anti-inflammatory therapeutics. The Italian start-up plans to tag already-approved compounds with an H2S-releasing molecule. The strategy has several potential advantages: it would create novel chemical entities, it would reduce the risks of drug development, and it could be applied with a variety of drugs.

GeneMedix's Big Biogeneric Gamble

Patent expiries in Europe on proteins such as EPO and interferon alpha may open up a huge market for cheaper versions of these proteins-one which GeneMedix and others are preparing to tap into. But it's a risky game, since there's still no regulatory process in Europe for approving such products.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts